Immunovant (IMVT) Earnings Date, Estimates & Call Transcripts $15.25 -0.28 (-1.82%) As of 12:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immunovant Earnings Summary Immunovant released Q1 2026 earnings on August 11, 2025, reporting an EPS of -$0.60, which topped the consensus estimate of -$0.69 by $0.09. With a trailing EPS of -$2.85, Immunovant's earnings are expected to decrease next year, from ($2.69) to ($3.08) per share. Upcoming Q2 Earnings DateNov. 6Before Market OpensEstimatedConsensus EPS (Aug. 11) -$0.69 Actual EPS (Aug. 11) -$0.60 Beat By $0.09 Q1 2026 Earnings ResourcesQ1 2026 Earnings Report Press Release (8-K) Quarterly Report (10-Q)SEC FilingIMVT Upcoming EarningsImmunovant's next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules. Powered by Get Immunovant Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataIMVT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Immunovant Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.57-$0.41-$0.50Q2 20254-$0.62-$0.54-$0.59Q3 20254-$0.64-$0.54-$0.59Q4 20254-$0.75-$0.56-$0.65 FY 2025 15 -$2.58 -$2.05 -$2.32 Q1 20262-$0.82-$0.62-$0.72Q2 20264-$0.87-$0.70-$0.77Q3 20264-$0.86-$0.70-$0.78Q4 20264-$0.88-$0.70-$0.78 FY 2026 14 -$3.43 -$2.72 -$3.05 Q1 20272-$0.91-$0.87-$0.89Q2 20272-$0.95-$0.89-$0.92Q3 20272-$0.96-$0.91-$0.94Q4 20271-$0.92-$0.92-$0.92 Immunovant Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/6/2025(Estimated)--------8/11/2025Q1 2026-$0.69-$0.60+$0.09-$0.71--5/29/2025Q4 2025-$0.72-$0.64+$0.08-$0.64-$0.16M2/10/2025Q3 2025-$0.68-$0.76 -$0.08-$0.76--11/7/2024Q2 2025-$0.59-$0.74 -$0.15-$0.74--8/6/2024Q1 2025-$0.53-$0.60 -$0.07-$0.60--5/29/2024Q4 2024-$0.44-$0.52 -$0.08-$0.52--2/12/2024Q3 2024-$0.43-$0.36+$0.07-$0.36--11/9/2023Q2 2024-$0.45-$0.45--$0.45-- Immunovant Earnings - Frequently Asked Questions When is Immunovant's earnings date? Immunovant has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based off last year's report dates. Learn more on IMVT's earnings history. Did Immunovant beat their earnings estimates last quarter? In the previous quarter, Immunovant (NASDAQ:IMVT) reported ($0.60) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.69) by $0.09. Learn more on analysts' earnings estimate vs. IMVT's actual earnings. How can I view Immunovant's earnings report? Immunovant's earnings report can be found in their filing with the SEC. View SEC filing How much profit does Immunovant generate each year? Immunovant (NASDAQ:IMVT) has a recorded net income of -$413.84 million. IMVT has generated -$2.85 earnings per share over the last four quarters. What is Immunovant's EPS forecast for next year? Immunovant's earnings are expected to decrease from ($2.69) per share to ($3.08) per share in the next year. More Earnings Resources from MarketBeat Related Companies Soleno Therapeutics Earnings QIAGEN Earnings BridgeBio Pharma Earnings Moderna Earnings Verona Pharma PLC American Depositary Share Earnings Elanco Animal Health Earnings Roivant Sciences Earnings Revolution Medicines Earnings Rhythm Pharmaceuticals Earnings Legend Biotech Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner This page (NASDAQ:IMVT) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMVT Stock Alerts